I founded Mango Inc. to bring lensless imaging technology into practical use for the first time. Recognizing its untapped potential, I focused on microbial quality control in pharmaceutical manufacturing—a critical barrier to continuous production.With our first $12 million in funding, we achieved our first commercial sale and secured partnerships with two Fortune 500 pharmaceutical companies. By carefully managing resources and avoiding overspending, we maximized investor value and minimized dilution.I led the development of a real-time microbial QC solution that integrated lensless imaging with machine learning and computer vision. This innovation enabled real-time continuous manufacturing and opened a $20 billion market.Key Achievements: • Innovation: Commercialized a groundbreaking technology where others had not succeeded, solving a critical industry problem and unlocking new market opportunities. • Leadership: Built and guided a multidisciplinary team, navigating challenges—including the COVID-19 pandemic—and fostering a culture of resilience and innovation. • Efficiency: Delivered significant milestones with limited capital, demonstrating strategic resource management and providing strong returns for investors.Inspired by companies like Patagonia, I aimed to create technology that not only achieves commercial success but also contributes positively to the industry and society. By aligning an innovative technology with a real market need, we laid the groundwork for future applications in diagnostics, drug discovery, and beyond.

(Acquired by Takeda)As Director of Product Strategy, I had the opportunity to lead a talented team in transforming a $1.2 billion division into a driver of innovation and growth. Working through challenges like global market complexities and shifting industry demands, we focused on what mattered—clear strategy, thoughtful execution, and teamwork.One of our proudest achievements was delivering 20% year-over-year growth, not through shortcuts or flashy campaigns, but by carefully aligning our vision with practical, on-the-ground execution. We launched new products that reached markets across the world, ensuring each one was tailored to the specific needs of those regions.Throughout, my role involved partnering closely with senior leadership to craft strategies that made a real difference—not just on paper, but in the way we operated and grew as a company. It wasn’t about grand gestures or sweeping changes; it was about finding smart, steady ways to build success and keep momentum going, even during uncertain times.

(Acquired by LabCorp)As an Entrepreneur-in-Residence at Metamark Genetics, I launched ProMark, a novel prostate cancer diagnostic tool that fills the critical need for accurate, non-invasive testing. This role enabled me to turn complex genetic research into a practical solution that benefits both patients and clinicians.I transitioned to Head of Product Development, guiding a diverse team through product development challenges and cultivating a culture of creativity and resilience. I secured twelve strategic partnerships with antibody suppliers, negotiating essential IP licensing agreements that strengthened our market capabilities.My commitment to aligning technology with real-world needs ensured our advancements in genetic diagnostics made a meaningful impact on patient care.

As a Drug Discovery Maverick, I led five international programs that screened an impressive 1.2 million compounds, redefining the frontiers of pharmaceutical research. My innovative strategies and predictive insights laid the foundation for next-generation therapeutic breakthroughs.In my role, I designed and implemented a lab-on-a-chip drug discovery platform, a compact system that captured the attention of executives and secured essential approvals. I developed pioneering assays to analyze glucose modulation in cancer cells and investigated the complex interactions of compounds and enzymes.My proactive approach to error prevention saved us from 60,000 potential mistakes through custom detection methods, significantly reducing false positives. I guided four novel compound classes from initial discovery to medicinal chemistry, accelerating their journey toward potential cures.By blending molecular biology, nanotechnology, and predictive algorithms, I didn’t just participate in drug discovery; I reimagined its landscape, setting the stage for a pharmaceutical renaissance. My commitment to innovation and precision continues to drive transformative advances in the field

At Johns Hopkins, I led a transformative initiative that established a 10,000 sq. ft. nexus for drug discovery, antibody development, and tissue banking. By bringing together a talented team of 16 professionals—including professors, vendors, architects, grant specialists, and administrators—I transformed theoretical potential into a state-of-the-art research facility.In this role, I architected a complex network of interconnected systems, guiding the project from concept to completion. I crafted compelling narratives that secured significant funding, effectively turning innovative ideas into capital. My attention to detail allowed me to develop comprehensive blueprints that connected visionary science with practical implementation.Through strategic vendor negotiations, I optimized resources and transformed interactions into valuable partnerships. Like decoding the building blocks of the universe, I distilled complex, multidisciplinary requirements into a coherent and world-class research environment.

I co-founded Canada’s leading Biocomplexity Institute with the mission to connect Nobel-level science with billion-dollar breakthroughs, harnessing modern AI to drive innovation.Under the guidance of Nobel Laureates Murray Gell-Mann and Stuart Kauffman, I pioneered the Institute and developed massively parallel complex systems that transformed genomics and drug discovery. By patenting the integration of parallel computing, genomics, and chemical biology, I established new benchmarks for innovation in the field.Utilizing genetic algorithms and information theory, I delivered a state-of-the-art drug discovery platform ten months ahead of schedule and 35% under budget. I also secured a groundbreaking international siRNA library deal, significantly enhancing our research capabilities through advanced computational methods.Much like my mentor’s work with quarks, I thrive on finding order in chaos. I translate intricate scientific principles into impactful biotech solutions, paving the way for advancements that resonate with today’s AI-driven landscape.Imagine a future where diseases are predicted before symptoms arise, and drugs are tailored to individual DNA—that’s the vision I’m working to bring to life through my expertise in complex systems and computational biology.